Following the landmark discovery that MYC translocates to the immunoglobulin loci in human and murine plasmacytoma cells in the early 1980s [7, 8], subsequent studies demonstrated that MYC dysregulation occurs in ∼50% of newly diagnosed MM patients and is associated with decreased progression-free (PFS) and OS. This evidence concerns the gene MYC and Miyoshi myopathy.